CrossTumor Evidence Mapping of PSMA Expression: Ranked Scoping Analysis of 171 Human Studies (EANM 2026) - Sep 29, 2026 - Abstract #EPS-055; Pres time: Oct 18, 2026; 03:00 PM - 04:30 PM; Location: Hall G2; "Diagnostic PSMA-PET largely used 68Ga-PSMA tracers with growing use of 18F-PSMA radiopharmaceuticals; theranostic applications were limited (n= 11; mainly [177Lu]Lu PSMA 617)... Non-prostatic PSMA expression is well documented and biologically plausible, most consistently manifesting in tumor neovasculature. To translate findings into clinical utility we recommend: (1) harmonized imaging protocols (standard tracer selection, uptake window); (2) prospective multicenter diagnostic accuracy trials in top ranked tumor(s) with prespecified endpoints and sample size justification; (3) mandatory histopathology-PET correlation studies to resolve localization and eligibility criteria for therapy; and (4) disease-specific dosimetry and early phase theranostic trials with tailored delivery strategies where PET uptake is robust. Implementing these steps will enable assessment of clinical impact, safe therapeutic translation, and increase resources for PSMA directed oncology..."
Brain Cancer • CNS Tumor • Genito-urinary Cancer • Glioblastoma • Hepatocellular Cancer • Oncology • Prostate Cancer • Renal Cell Carcinoma • Solid Tumor • Thyroid Gland Carcinoma • FOLH1
|
|
T. Ebenhan 1, 2; W. Cordier 1; C. A. Gouws 1, 2; M. M. Sathekge 3, 2; M. T. Tshabalala 1, 2
|